E7070

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer

Trial Timeline

Feb 1, 2005 → Aug 1, 2006

NCT ID

NCT00165594

About E7070

E7070 is a phase 1/2 stage product being developed by Eisai for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00165594. Target conditions include Gastric Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Gastric Cancer were approved

Approved (5) Terminated (3) Active (13)

✅ApatinibTabletsJiangsu Hengrui MedicineApproved

✅ApatinibJiangsu Hengrui MedicineApproved

✅Esomeprazole SodiumAstraZenecaApproved

✅trastuzumab [Herceptin]RocheApproved

✅Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placeboPfizerApproved

🔄Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00165867	Phase 2	Completed	Apr 1, 2005	—	Colorectal Cancer
NCT00165594	Phase 1/2	Terminated	Feb 1, 2005	Aug 1, 2006	Gastric Cancer
NCT00165880	Phase 2	Terminated	Dec 1, 2004	Sep 1, 2007	Metastatic Breast Cancer
NCT00080197	Phase 2	Completed	Feb 1, 2004	May 1, 2005	Breast Neoplasms
NCT00165854	Phase 2	Completed	Mar 1, 2003	—	Colorectal Cancer (CRC)
NCT00059735	Phase 2	Completed	May 1, 2002	Dec 1, 2003	Kidney Neoplasms

Competing Products

20 competing products in Gastric Cancer

See all competitors

Product	Company	Stage	Hype Score
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
Infigratinib	LianBio	Phase 2	17
Infigratinib	LianBio	Phase 2	21
Ramucirumab + MEDI4736	Eli Lilly	Phase 1	29
Ramucirumab	Eli Lilly	Phase 2	35
Trastuzumab + Capecitabine + Cisplatin	Celltrion	Phase 2	31
Trastuzumab + Fluorouracil + Cisplatin + Capecitabine	Chugai Pharmaceutical	Phase 3	40
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 2	42
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan + Ramucirumab + Paclitaxel	Daiichi Sankyo	Phase 3	44
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Bevacizumab	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan (T-DXd)	Daiichi Sankyo	Pre-clinical	33
DS-8201a	Daiichi Sankyo	Phase 1	29
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Irinotecan + Nimotuzumab	Daiichi Sankyo	Phase 3	32
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + Chemotherapy	Daiichi Sankyo	Phase 3	47
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	39